IBP Stock +106.23% Since Nov ’07 Pick IBP Stock +106.23% Since Nov ’07 Pick Unlock Top Buy Picks

Range Low Price High Price Comment
30 days $61.33 $75.66 Friday, 12th Apr 2024 CYTK stock ended at $71.56. This is 2.23% less than the trading day before Thursday, 11th Apr 2024. During the day the stock fluctuated 4.46% from a day low at $70.61 to a day high of $73.76.
90 days $61.33 $86.63
52 weeks $25.98 $110.00

Historical Cytokinetics prices
JSON

CSV

Date Open High Low Close Volume
2024-04-12 $73.76 $73.76 $70.61 $71.56 789 372
2024-04-11 $74.99 $75.50 $72.39 $73.19 741 450
2024-04-10 $72.54 $74.94 $72.30 $74.36 803 120
2024-04-09 $74.20 $75.66 $73.43 $75.05 1 211 190
2024-04-08 $73.90 $74.38 $72.55 $74.19 953 333
2024-04-05 $69.21 $73.21 $68.43 $72.71 976 544
2024-04-04 $71.69 $72.31 $68.72 $69.18 715 558
2024-04-03 $70.27 $71.43 $70.00 $70.92 574 388
2024-04-02 $71.19 $72.72 $70.35 $70.97 997 255
2024-04-01 $69.78 $73.16 $68.90 $73.02 1 347 535
2024-03-28 $71.41 $71.86 $69.96 $70.11 1 611 905
2024-03-27 $71.40 $73.18 $69.88 $71.41 1 879 574
2024-03-26 $69.00 $74.67 $68.28 $71.15 3 998 598
2024-03-25 $67.75 $69.40 $67.64 $68.73 969 189
2024-03-22 $65.79 $68.33 $65.13 $67.42 1 411 838
2024-03-21 $67.90 $68.87 $65.77 $66.03 1 457 982
2024-03-20 $66.81 $67.96 $65.64 $67.36 1 445 580
2024-03-19 $63.64 $69.18 $63.41 $67.59 2 480 217
2024-03-18 $65.35 $68.35 $63.65 $63.75 2 008 455
2024-03-15 $63.43 $65.44 $62.37 $65.19 20 953 124
2024-03-14 $64.37 $64.47 $61.33 $63.75 2 645 644
2024-03-13 $65.33 $65.80 $63.50 $64.63 2 056 534
2024-03-12 $65.00 $66.00 $62.62 $64.55 2 368 962
2024-03-11 $65.82 $66.45 $62.16 $64.39 2 610 136
2024-03-08 $67.00 $68.24 $65.71 $65.75 1 306 225
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT